interesting, but so where our EIND results. I'm not here to bash the study, but the article looks like a ransom note, and they hardly tested this on anyone.

Excerpts:
Patients over 65, or those under 65 but who are overweight or have multiple health problems, qualify as high-risk for treatment with the drug. For patients under 65, it’s “about looking at the combination of weight” and other factors, Sabo said.

So those people who are at the highest risk of dying aren't allowed to have the drug.

In the new study, investigators tracked four hospitalizations and zero deaths among patients who received the Lilly antibody combo. That compared with 11 hospitalizations and four deaths for patients on placebo.

A whopping 4 people they followed that got the drug and 15 placebos...4 of which died? (so a subset of 19 people and only 4 got the drug?? who's cherry picking subsets of data now?)

I'm missing something here because usually big pharma comes out with huge numbered trials and all the numbers here seem cherry picked...you know subsets of data...the thing CYDY was accused of doing. I'm happy for the patients that got better and wouldn't mind it at all if it worked, but this isn't any different than our PR.